MetaVia Inc. to Present Key Findings on DA-1726 at ObesityWeek® 2026 in Washington, D.C.
MetaVia Inc. to Showcase DA-1726 at ObesityWeek® 2026
MetaVia Inc., a biotechnology company listed on Nasdaq (MTVA), is poised to make a significant impact at the upcoming ObesityWeek® 2026, scheduled from November 14-17, 2026 in Washington, D.C. The event will host presentations and discussions focused on obesity and related metabolic disorders, with MetaVia specifically highlighting its novel investigational drug, DA-1726.
This innovative treatment is notable for its dual action as an analog of oxyntomodulin (OXM), uniquely engaging both the GLP-1 (GLP-1 receptor) and glucagon (GCGR) receptors. The acceptance of an abstract for a poster presentation is not just an opportunity for MetaVia but a testament to the potential of DA-1726 in addressing pivotal cardiometabolic diseases that contribute significantly to global health challenges.
Presentation Details
The poster presentation titled “DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide” will take place during the Gut Peptides, Appetite Signaling & Novel Therapeutics session. The lead presenter will be Il Hoon Jeong, MS, a respected Research Scientist from Dong-A ST Research Center. Participants and attendees can look forward to:
- - Session Date: Saturday, November 14, 2026
- - Session Time: 7:30 PM - 8:30 PM ET
- - Poster Number: Poster-229
- - Session Location: Exhibit Hall BC
Following the presentation, an electronic version of the poster will be accessible in the Posters section of MetaVia's official website. This will allow wider engagement with the findings for those unable to attend.
About DA-1726
DA-1726 represents a significant advancement among therapeutics aimed at cardiometabolic conditions, particularly Metabolic and Alcohol-Associated Liver Diseases (MetALD and ALD). Designed for once-weekly subcutaneous administration, DA-1726 functions effectively as a dual agonist, thus promoting weight loss through appetite suppression and enhanced energy expenditure.
Clinical data has begun to emerge from a Phase 1 Part 3B interim analysis, revealing promising results: DA-1726 has demonstrated a 13.5% reduction in body weight compared to placebo, alongside a 68% decrease in liver fat. Moreover, reductions in both visceral and subcutaneous fat were observed while preserving lean muscle mass, substantiating the drug's efficacy.
The mechanistic action of DA-1726—a carefully engineered ratio of GLP1R and GCGR activation—is pivotal, as it harnesses the complementary effects of both receptors to optimize weight and metabolic health. This innovation could position DA-1726 as a cornerstone therapy in the management of obesity and its associated complications.
Future Prospects
Looking ahead, MetaVia is gearing up for a Phase 2, 48-week, non-biopsy study targeting MetALD and ALD, expected to initiate in the latter half of 2027. This trial aims to further elucidate DA-1726's potential and enhances the profile of MetaVia as a transformative entity in the biotechnology landscape dedicated to tackling cardiometabolic diseases.
Conclusion
MetaVia’s participation at ObesityWeek® 2026 represents not just a milestone for the company but also a beacon of hope for patients grappling with obesity-related metabolic disorders. With DA-1726 demonstrating such promise, the future of cardiometabolic treatment is looking more innovative than ever. For those interested in following MetaVia’s journey, more information is available on their official website www.metaviatx.com.
This event marks a critical juncture for MetaVia Inc. as it merges cutting-edge science with the pressing health needs of our time.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.